Covalent tyrosine kinase inhibitors bind and inhibit wild-type EGF:EGFR dimers

Stable Identifier
R-HSA-1225978
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Covalent (irreversible) TKIs, pelitinib, WZ4002, HKI-272, canertinib and afatinib, inhibit the wild-type EGFR through formation of the covalent bond with the cysteine residue C397.

Literature References
PubMed ID Title Journal Year
20033049 Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W, Ercan, D, Chen, L, Yun, CH, Li, D, Capelletti, M, Cortot, AB, Chirieac, L, Iacob, RE, Padera, R, Engen, JR, Wong, KK, Eck, MJ, Gray, NS, Jänne, PA

Nature 2009
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!